查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924674

人類高免疫球蛋白市場按產品類型、給藥途徑、應用和最終用戶分類－2026-2032年全球預測

Human Hyperimmune Globulins Market by Product Type, Route of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年人類高免疫球蛋白市場價值為9.5993億美元，預計到2026年將成長至10.424億美元，年複合成長率為9.52%，到2032年將達到18.1498億美元。

關鍵市場統計數據
基準年 2025 9.5993億美元
預計年份：2026年 10.424億美元
預測年份 2032 1,814,980,000 美元
複合年成長率 (%) 9.52%

本文重點介紹高免疫球蛋白療法，概述其臨床作用、生產實際情況、監管考慮因素和策略准入意義。

人類高免疫球蛋白（HIG）是一種由混合人類血漿製成的特殊免疫球蛋白療法，對特定病原體具有高效價。它可用作高危險暴露期間的預防性和標靶治療藥物，在感染疾病控制、輸血醫學和急診護理的交叉領域中發揮著至關重要的作用。其臨床適應症涵蓋了從已知暴露後預防病原體傳播到為其自體免疫不足的脆弱患者群體提供輔助性治療，使其成為現代臨床工具包中不可或缺的生物製藥部分。

新興的臨床需求、製造創新和政策轉變正在共同改變高免疫球蛋白產品的供應、需求和獲取動態。

高免疫球蛋白領域正經歷一系列變革，這些變革由臨床、技術和政策因素共同驅動，重塑供需平衡。在臨床上，為滿足臨床醫師對更精準的暴露後預防方案和免疫力缺乏患者輔助性治療的需求，標靶免疫球蛋白的應用範圍正在不斷擴大。同時，供體篩檢和病原體特異性抗體定量方法的創新正在提高產品的一致性，使生產商能夠更好地根據臨床需求調整生產，同時降低效力和安全性方面的差異。

近期關稅措施對血漿衍生免疫球蛋白療法的籌資策略、合規負擔和供應鏈韌性的影響

各國實施的海關政策和貿易措施會對血漿衍生療法的供應、成本結構和籌資策略產生連鎖反應。近期關稅調整促使企業重新檢視全球籌資策略，迫使生產者和經銷商重新評估跨境物流、供應商多元化和庫存緩衝。與關稅歸類和清關相關的合規負擔也隨之增加，推高了行政成本，迫使企業投入更多資源用於貿易合規、供應計畫和合約保障。

詳細的細分觀點揭示了產品類型、臨床應用、醫療環境、給藥途徑和分銷管道如何驅動差異化需求和業務重點。

細分市場分析揭示了不同產品類型、適應症、臨床環境、給藥途徑和分銷管道之間的顯著差異，這些差異共同指南商業化和臨床導入策略。產品組合的考慮範圍涵蓋巨細胞病毒免疫球蛋白、 B型肝炎免疫球蛋白、狂犬病免疫球蛋白、破傷風免疫球蛋白和水痘-帶狀皰疹免疫球蛋白，每種產品都有不同的臨床路徑、供體抗體譜和生產產能需求。這些產品特有的特性會影響生產計畫的優先排序，以及製造商如何分配高效價血漿以滿足最迫切的臨床需求。

影響全球市場採購優先事項、供應安全和監管協調的區域比較趨勢和基礎設施因素

區域趨勢對籌資策略、監管溝通和生產力計畫至關重要，因為不同地區的醫療基礎設施、捐血者資源和報銷環境各不相同。在美洲，成熟的醫療體系和完善的血漿採集網路為急診和門診提供了穩定的產品供應。然而，區域監管審查和物流方面的考量會影響前置作業時間和分銷範圍。該地區的醫療機構傾向於優先整合循證通訊協定，用於暴露後預防和標靶治療，從而維持醫院藥房和專科診所可預測的需求模式。

HyperImmune價值鏈中，血漿來源、產品品質和臨床實施彈性均由策略性企業能力和夥伴關係模式決定。

主要商業企業和生產網路之間的差異體現在其對血漿來源、生產規模、品質保證措施以及整個供應鏈策略夥伴關係關係的控制。擁有整合血漿採集和分離能力的企業通常能夠更靈活地應對突如其來的需求高峰，並確保不同批次產品抗體滴度的一致性。同時，專業生產商和合約分離商憑藉其靈活的生產能力和專業技術，發揮關鍵作用，使治療申辦方能夠快速擴大生產規模或專注於特定的高免疫標靶。

為製造商和醫療保健提供者提供切實可行的策略措施，以加強供應鏈基礎、協調臨床應用並運作具有彈性的分銷模式。

產業領導者應優先投資於能夠增強供應韌性、加強臨床應用協調以及簡化監管和商業化流程的專案。加強國內血漿採集系統並擴大與信譽良好的血漿分離商的策略合作，將有助於降低跨境供應中斷的風險，同時更好地管理抗原特異性捐贈者庫。此外，投資先進的捐贈者篩檢和抗體定量工具，將提高批次間一致性，並為臨床優先使用稀有高效價血漿提供基礎。這些技術投資必須與穩健的合約框架相匹配，以應對關稅波動並確保在壓力情境下也能有效運作。

我們的混合方法研究途徑結合了關鍵相關人員訪談、監管審查、工作流程圖繪製和情境分析，以建立可靠的策略指導。

本研究採用混合方法，整合了相關人員訪談、監管文件、供應鏈分析和同行評審的臨床文獻，以建構高免疫球蛋白生態系統的全貌。研究人員從臨床醫生、醫院藥劑師、生產專家和供應鏈管理人員收集了主要的定性資訊，以了解臨床實際情況、臨床決策促進因素和產品管理實踐。這些發現與包括監管指南、生產標準和公開的生產流程資訊在內的二級資訊來源進行了交叉核對，以確保數據的一致性並識別已發表數據的不足之處。

臨床相關性、供應鏈需求和策略重點的綜合考量將決定高免疫療法的可及性和營運永續性。

總之，在技術先進且策略敏感的供應鏈中，高免疫球蛋白仍是針對性預防和支持性臨床治療的重要選擇。由於暴露事件和脆弱患者群體，臨床需求突發且至關重要，而生產和分銷動態要求持續關注捐贈者招募、產品一致性和物流。積極投資於供應鏈韌性、協同採購和循證臨床路徑的相關人員將更有能力確保患者及時獲得治療，並控制成本和營運風險。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 人類高免疫球蛋白市場（依產品類型分類）

  • 巨細胞病毒免疫球蛋白
  • B型肝炎免疫球蛋白
  • 狂犬病免疫球蛋白
  • 破傷風免疫球蛋白
  • 水痘-帶狀皰疹免疫球蛋白

9. 依給藥途徑分類的人高免疫球蛋白市場

  • 肌肉內注射
  • 靜脈注射
  • 皮下注射

第10章 人類高免疫球蛋白市場（按應用分類）

  • 暴露後預防
    • 動物咬傷
    • 輸血暴露
    • 針刺傷
  • 治療用途

第11章 人類高免疫球蛋白市場（以最終用戶分類）

  • 門診治療中心
  • 診所
  • 醫院

12. 各地區人高免疫球蛋白市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 人類高免疫球蛋白市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國人高免疫球蛋白市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國人類高免疫球蛋白市場

第16章：中國人類高免疫球蛋白市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ADMA Biologics, Inc.
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring LLC
  • Emergent BioSolutions Inc.
  • Fresenius Kabi AG
  • GC Biopharma Co., Ltd.
  • Grifols, SA
  • Hualan Biological Engineering, Inc.
  • Kamada Ltd.
  • Kedrion SpA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-7A380DA7C417

The Human Hyperimmune Globulins Market was valued at USD 959.93 million in 2025 and is projected to grow to USD 1,042.40 million in 2026, with a CAGR of 9.52%, reaching USD 1,814.98 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 959.93 million
Estimated Year [2026] USD 1,042.40 million
Forecast Year [2032] USD 1,814.98 million
CAGR (%) 9.52%

A focused orientation to hyperimmune globulin therapies outlining clinical roles, manufacturing realities, regulatory considerations, and strategic access implications

Human hyperimmune globulins represent a specialized class of immunoglobulin therapies derived from pooled human plasma with high titers against specific pathogens. Used both as prophylaxis in high-risk exposures and as targeted therapeutics, these products occupy a critical niche at the intersection of infectious disease management, transfusion medicine, and emergency care. Clinical indications span prevention of pathogen transmission after known exposures and adjunctive therapy for vulnerable patient populations who lack sufficient endogenous immunity, positioning these biologics as essential components of contemporary clinical toolkits.

Beyond clinical utility, the landscape for hyperimmune globulins is shaped by complex supply chains, donor recruitment dynamics, regulatory oversight, and evolving standards for plasma-derived product manufacturing. Recent advances in assay technologies and donor screening have improved specificity and safety, yet manufacturing remains resource intensive, requiring concentrated plasma inputs and validated fractionation processes. As a result, stakeholders from clinicians to procurement officers must weigh operational constraints, logistical timelines, and evolving clinical guidelines when integrating hyperimmune globulins into care pathways. This introduction frames the subsequent analysis by highlighting clinical roles, production realities, and the strategic considerations that influence adoption and access.

Emerging clinical imperatives, manufacturing innovations, and policy shifts that are jointly transforming supply, demand, and access dynamics for hyperimmune globulin products

The hyperimmune globulin landscape is undergoing a set of transformative shifts driven by clinical, technological, and policy forces that are reshaping supply-demand equilibria. Clinically, expanded use cases for targeted immunoglobulins are emerging as clinicians seek more precise post-exposure prophylaxis options and adjunctive therapies for immunocompromised patients. Concurrently, innovations in donor screening and pathogen-specific antibody quantification have improved product consistency, enabling manufacturers to better align production with clinical need while reducing variability in potency and safety profiles.

From a systems perspective, consolidation within plasma collection and fractionation networks, together with strategic partnerships between biopharma and specialty manufacturers, is altering how capacity and capability are allocated. Regulatory agencies are also updating guidance around pathogen testing and lot release criteria, which increases transparency but can lengthen time-to-market for new lots. At the same time, digital health tools and data analytics are enabling more responsive inventory management and demand forecasting for hospital pharmacies and clinics, smoothing distribution while exposing vulnerabilities when supply chain shocks occur. Taken together, these shifts are creating both opportunities for targeted expansion and new risks that require coordinated risk management and strategic investment.

How recent tariff measures are reshaping sourcing strategies, compliance burdens, and supply chain resilience for plasma-derived immunoglobulin therapies

Tariff policies and trade measures enacted at national levels can have cascading effects on the availability, cost structure, and sourcing strategies for plasma-derived therapies. Recent tariff adjustments have incentivized a re-examination of global sourcing strategies, prompting manufacturers and distributors to reassess cross-border logistics, supplier diversification, and inventory buffers. Compliance burdens associated with tariff classifications and customs procedures also increase administrative overhead, driving organizations to allocate additional resources to trade compliance, supply planning, and contractual protections.

Importantly, tariff-driven cost pressures often translate into strategic shifts rather than immediate clinical changes. Manufacturers may respond by optimizing regional production footprints, lengthening supply agreements with local plasma collection sites, or accelerating investments in domestic fractionation capacity to mitigate exposure to border costs. Healthcare providers and procurement teams may prioritize procurement strategies that favor multi-source agreements and longer lead-times to absorb variability. In summary, while tariffs introduce friction and incremental cost considerations, the more consequential impacts manifest through altered sourcing patterns, supply chain resilience strategies, and the reallocation of capital toward capacity localization and compliance infrastructure.

In-depth segmentation perspectives revealing how product types, clinical applications, care settings, administration routes, and distribution channels drive differentiated demand and operational priorities

Segment-level analysis reveals differentiated dynamics across product types, indications, care settings, administration routes, and distribution channels that jointly inform commercialization and clinical adoption strategies. Product mix considerations range from Cytomegalovirus Immunoglobulin to Hepatitis B Immunoglobulin, Rabies Immunoglobulin, Tetanus Immunoglobulin, and Varicella Zoster Immunoglobulin, each governed by distinct clinical pathways, donor antibody profiles, and manufacturing throughput demands. These product-specific characteristics affect prioritization in production schedules and influence how manufacturers allocate high-titer plasma to meet the most time-sensitive clinical needs.

Application-driven segmentation distinguishes post-exposure prophylaxis from therapeutic use, with post-exposure demands further differentiated by exposure type such as animal bite, blood transfusion exposure, and needlestick injury. These clinical scenarios produce episodic but urgent demand patterns that require rapid distribution and robust inventory planning. End users span ambulatory care centers, clinics, and hospitals, each with unique procurement cycles, reimbursement frameworks, and cold-chain logistics. Route of administration considerations, including intramuscular, intravenous, and subcutaneous delivery, have implications for product formulation, nursing workflows, and outpatient versus inpatient use. Distribution channel dynamics encompass hospital pharmacy, online pharmacy, and retail pharmacy pathways, each presenting trade-offs in terms of immediacy of access, inventory holding models, and regulatory compliance. Integrating these segmentation lenses enables stakeholders to identify highest-impact interventions across clinical, operational, and commercial dimensions.

Comparative regional dynamics and infrastructure considerations that influence procurement priorities, supply security, and regulatory alignment across global markets

Regional dynamics are central to procurement strategies, regulatory interactions, and capacity planning as geographic markets exhibit distinct healthcare infrastructures, donor base availability, and reimbursement environments. In the Americas, mature healthcare systems and established plasma collection networks provide a foundation for steady product flow to both acute and outpatient settings, yet regional regulatory reviews and logistics considerations influence lead times and distribution footprints. Healthcare institutions in this region tend to emphasize integration of evidence-based protocols for post-exposure prophylaxis and targeted therapeutic use, supporting predictable demand patterns in hospital pharmacies and specialized clinics.

Europe, Middle East & Africa present a heterogeneous picture where regulatory harmonization efforts coexist with significant variance in plasma collection capacity and reimbursement frameworks. Certain subregions prioritize local manufacturing incentives and supply security policies, which affect how manufacturers approach regional investments and partnership models. Meanwhile, Asia-Pacific markets are characterized by rapidly evolving infrastructure, growing demand in urban referral centers, and active investment in domestic plasma fractionation capabilities. Across these regions, stakeholders balance priorities between supply security, cost containment, and clinical access, adopting region-specific strategies for donor engagement, cold-chain logistics, and regulatory alignment to ensure continuity of care.

Strategic company capabilities and partnership models that determine agility in plasma sourcing, production quality, and clinical adoption across the hyperimmune value chain

Key commercial players and manufacturing networks are differentiated by their control over plasma sourcing, manufacturing scale, quality assurance practices, and strategic partnerships across the supply chain. Organizations that maintain integrated plasma collection and fractionation capabilities typically have greater agility in responding to episodic surges in demand and in ensuring consistent antibody titers across product lots. Conversely, specialist manufacturers and contract fractionators play an important role by offering flexible capacity and niche expertise, enabling therapeutic sponsors to scale rapidly or to focus on particular hyperimmune targets.

Collaboration between clinical communities and manufacturers is increasingly important for product stewardship, lot traceability, and post-market surveillance. Firms that invest in transparent quality metrics and that foster strong relationships with hospital pharmacies and clinician advisory groups can reduce friction in adoption and create preferred-supplier dynamics. Additionally, partnerships that extend into diagnostics and donor screening technologies enhance the ability to produce higher-titer, pathogen-specific immunoglobulins. Ultimately, competitive advantage accrues to organizations that combine reliable plasma access, rigorous manufacturing controls, and proactive engagement with healthcare stakeholders to align supply with clinical needs.

Practical strategic moves for manufacturers and healthcare providers to fortify supply, align clinical use, and operationalize resilient distribution models

Industry leaders should prioritize investments that increase supply resilience, enhance clinical alignment, and streamline regulatory and commercial pathways. Strengthening domestic plasma collection and expanding strategic partnerships with trusted fractionators will reduce exposure to cross-border disruptions while enabling better control over antigen-specific donor pools. At the same time, investing in advanced donor screening and antibody quantification tools will improve lot consistency and inform clinical prioritization for scarce high-titer material. These technical investments should be paired with robust contractual frameworks designed to protect against tariff variability and to ensure performance under stress scenarios.

On the demand side, proactive engagement with clinicians and pharmacy leaders to develop standardized protocols for post-exposure prophylaxis and therapeutic use will reduce variability in ordering patterns and support predictable consumption. Establishing joint forecasting and inventory sharing arrangements between hospitals, ambulatory centers, and clinics can smooth episodic demand, while tailored distribution agreements with hospital pharmacies, online pharmacy platforms, and retail pharmacy networks will expand access pathways. Finally, aligning value propositions with payers and regulatory stakeholders through evidence generation and health economic analyses will facilitate reimbursement clarity and support broader clinical adoption.

A mixed-methods research approach combining primary stakeholder interviews, regulatory review, operational mapping, and scenario analysis to underpin robust strategic guidance

This research synthesis draws upon a mixed-methods approach that integrates stakeholder interviews, regulatory documentation, supply chain analysis, and peer-reviewed clinical literature to build a holistic picture of the hyperimmune globulin ecosystem. Primary qualitative inputs were sought from clinicians, hospital pharmacists, manufacturing experts, and supply chain managers to capture operational realities, clinical decision drivers, and product stewardship practices. These insights were triangulated with secondary sources including regulatory guidance, manufacturing standards, and publicly reported production process information to ensure consistency and to expose gaps in public data.

Analytical techniques included process-mapping of plasma sourcing and fractionation workflows, scenario analysis for supply disruption and tariff impacts, and comparative regional assessment of regulatory and distribution frameworks. Emphasis was placed on validating assumptions through cross-validation of interview insights and documented policy positions. Where possible, methodological limitations and data gaps were identified so that readers can understand the confidence bounds around operational and strategic recommendations. The approach balances qualitative depth with systems-level analysis to produce actionable intelligence for clinicians, manufacturers, and procurement leaders.

Synthesis of clinical importance, supply chain imperatives, and strategic priorities that jointly determine access and operational sustainability for hyperimmune therapies

In conclusion, hyperimmune globulins remain a critical therapeutic option for targeted prophylaxis and adjunctive clinical care, situated within a supply chain that is both technically demanding and strategically sensitive. Clinical demand is episodic yet essential, driven by exposure events and vulnerable patient cohorts, while manufacturing and distribution dynamics require sustained attention to donor recruitment, product consistency, and logistics. Stakeholders that proactively invest in supply resilience, collaborative procurement, and evidence-based clinical pathways will be better positioned to ensure timely access for patients and to manage cost and operational risks.

Looking forward, the interplay of manufacturing innovation, regulatory evolution, and regional capacity expansion will continue to define access and availability. Organizations that align clinical education, supplier partnerships, and strategic investments in domestic capacity will realize the most durable benefits. The concluding message is clear: pragmatic, coordinated action across the value chain is essential to translate the therapeutic promise of hyperimmune globulins into reliable clinical outcomes and sustainable operational models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Hyperimmune Globulins Market, by Product Type

  • 8.1. Cytomegalovirus Immunoglobulin
  • 8.2. Hepatitis B Immunoglobulin
  • 8.3. Rabies Immunoglobulin
  • 8.4. Tetanus Immunoglobulin
  • 8.5. Varicella Zoster Immunoglobulin

9. Human Hyperimmune Globulins Market, by Route of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. Human Hyperimmune Globulins Market, by Application

  • 10.1. Post-Exposure Prophylaxis
    • 10.1.1. Animal Bite
    • 10.1.2. Blood Transfusion Exposure
    • 10.1.3. Needlestick Injury
  • 10.2. Therapeutic Use

11. Human Hyperimmune Globulins Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Human Hyperimmune Globulins Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Hyperimmune Globulins Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Hyperimmune Globulins Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Hyperimmune Globulins Market

16. China Human Hyperimmune Globulins Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ADMA Biologics, Inc.
  • 17.6. Bayer AG
  • 17.7. Bio Products Laboratory Ltd.
  • 17.8. Biotest AG
  • 17.9. China Biologic Products Holdings, Inc.
  • 17.10. CSL Behring LLC
  • 17.11. Emergent BioSolutions Inc.
  • 17.12. Fresenius Kabi AG
  • 17.13. GC Biopharma Co., Ltd.
  • 17.14. Grifols, S.A.
  • 17.15. Hualan Biological Engineering, Inc.
  • 17.16. Kamada Ltd.
  • 17.17. Kedrion S.p.A.
  • 17.18. Novartis AG
  • 17.19. Octapharma AG
  • 17.20. Pfizer Inc.
  • 17.21. Sanofi S.A.
  • 17.22. Shanghai RAAS Blood Products Co., Ltd.
  • 17.23. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 17.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY VARICELLA ZOSTER IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY VARICELLA ZOSTER IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY VARICELLA ZOSTER IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ANIMAL BITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ANIMAL BITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ANIMAL BITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY BLOOD TRANSFUSION EXPOSURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY BLOOD TRANSFUSION EXPOSURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY BLOOD TRANSFUSION EXPOSURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY NEEDLESTICK INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY NEEDLESTICK INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY NEEDLESTICK INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY THERAPEUTIC USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY THERAPEUTIC USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)